Microbot MedicalvsThermo Fisher Scientific

MBOT and TMO stock compared: price, dividend, valuation and results, from SEC filings.

MBOT

Microbot Medical Inc.

$0.68

Value $46M

-8.11%
MBOT's page

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

Microbot Medical (MBOT) has a market value of $46M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, MBOT moved -64.6% and TMO +17.1%. Dividend yield: MBOT none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MBOT$46M

    TMO$249B

    TMO is 5,446 times MBOT

  • Revenue, 12 months

    MBOT–

    TMO$47.4B

  • Net income, 12 months

    MBOT-$19M

    TMO$7.1B

  • Operating margin

    MBOT–

    TMO17.9%

  • ROIC

    MBOT-15.0%

    TMO8.2%

    23.2 points apart

  • P/E

    MBOT–

    TMO35.2

  • Dividend yield

    MBOT0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    MBOT-88.7%

    TMO+6.8%

    95.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MBOT-88.7%

TMO+6.8%

5010020222023202420252026
Returns by period
PeriodMBOTWith dividendsTMOWith dividends
1 year since November 19, 2025-64.6%Price -64.6%+17.1%Price +16.7%
3 years since November 20, 2023-50.4%-20.8% a yearPrice -50.4%+44.1%+13.0% a yearPrice +42.7%
5 years since November 19, 2021-88.7%-35.3% a yearPrice -88.7%+6.8%+1.3% a yearPrice +5.3%
10 years since November 22, 2016-99.6%-42.2% a yearPrice -99.6%+381.6%+17.0% a yearPrice +368.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MBOTMicrobot MedicalTMOThermo Fisher Scientific

Valuation

MBOTTMO
Valuation
Price$0.68$669.54
Market value$46M$249B
Enterprise value (EV)–$284B
P/E–35.2
P/E, 5-year median–32.7
P/B0.74.5
EV/EBIT–33.5
Free cash flow yield–3.1%

Results and growth

MBOTTMO
Results and growth
Revenue, 12 months–$47.4B
Net income, 12 months-$19M$7.1B
Free cash flow, 12 months-$20M$7.6B
Earnings per share, 12 months-$0.26$18.96
Revenue growth, year on year–3.9%
Revenue growth a year, past–+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

MBOTTMO
Margins and returns on capital
Gross margin––
Operating margin–17.9%
Net margin–14.9%
ROIC-15.0%8.2%
ROE-25.7%13.4%

Balance sheet

MBOTTMO
Balance sheet
Cash$62M$6.1B
Total debt$838.0K$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

MBOTTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MBOT or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Microbot Medical or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($249B) is about 5,445.9 times Microbot Medical ($46M), at today's prices.

How did MBOT and TMO stock do over the last 10 years?

Since November 22, 2016, MBOT's price moved -99.6% and TMO's +368.2%. With dividends: MBOT -99.6% (-42.2% a year), TMO +381.6% (+17.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, MBOT or TMO?

The dividend yield at today's price is none for Microbot Medical and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which is the better investment, Microbot Medical or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.